Your browser doesn't support javascript.
loading
Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation.
Toso, Christian; Meeberg, Glenda; Hernandez-Alejandro, Roberto; Dufour, Jean-François; Marotta, Paul; Majno, Pietro; Kneteman, Norman M.
Afiliación
  • Toso C; Divisions of Transplant and Abdominal Surgery, Department of Surgery, University of Geneva Hospitals, Geneva, Switzerland.
  • Meeberg G; Division of Transplantation, Department of Surgery, University of Alberta, Edmonton, Alberta, Canada.
  • Hernandez-Alejandro R; Multi-Organ Transplant Program, London Health Sciences Center, The University of Western Ontario, London, Ontario, Canada.
  • Dufour JF; University Clinic for Visceral Surgery and Medicine, Inselspital, University of Bern, Bern, Switzerland.
  • Marotta P; Multi-Organ Transplant Program, London Health Sciences Center, The University of Western Ontario, London, Ontario, Canada.
  • Majno P; Divisions of Transplant and Abdominal Surgery, Department of Surgery, University of Geneva Hospitals, Geneva, Switzerland.
  • Kneteman NM; Division of Transplantation, Department of Surgery, University of Alberta, Edmonton, Alberta, Canada.
Hepatology ; 62(1): 158-65, 2015 Jul.
Article en En | MEDLINE | ID: mdl-25777590
ABSTRACT
UNLABELLED The selection of liver transplantation (LT) candidates with hepatocellular carcinoma (HCC) is currently validated based on Milan criteria. The use of extended criteria has remained a matter of debate, mainly because of the absence of prospective validation. The present prospective study recruited patients according to the previously proposed total tumor volume (TTV; ≤115 cm(3) )/alpha-fetoprotein (AFP; ≤400 ng/mL) score. Patients with AFP >400 ng/mL were excluded, and, as such, the Milan group was modified to include only patients with AFP <400 ng/mL; these patients were compared to patients beyond Milan, but within TTV/AFP. From January 2007 to March 2013, 233 patients with HCC were listed for LT. Of them, 195 patients were within Milan and 38 beyond Milan, but within TTV/AFP. The average follow-up from listing was 33.9 ± 24.9 months. Risk of dropout was higher for patients beyond Milan, but within TTV/AFP (16 of 38; 42.1%), than for those within Milan (49 of 195 [25.1%]; P = 0.033). In parallel, intent-to-treat survival from listing was lower in patients beyond Milan (53.8% vs. 71.6% at 4 years; P < 0.001). After a median waiting time of 8 months, 166 patients were transplanted, 134 within Milan criteria, and 32 beyond Milan but within TTV/AFP. They demonstrated acceptable and similar recurrence rates (4.5% vs. 9.4%; P = 0.138) and post-transplant survivals (78.7% vs. 74.6% at 4 years; P = 0.932).

CONCLUSION:

Based on the present prospective study, HCC LT candidate selection could be expanded to the TTV (≤115 cm(3) )/AFP (≤400 ng/mL) criteria in centers with at least 8-month waiting time. An increased risk of dropout on the waiting list can be expected, but with equivalent and satisfactory post-transplant survival.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Alfa-Fetoproteínas / Trasplante de Hígado / Carcinoma Hepatocelular / Hígado / Neoplasias Hepáticas Tipo de estudio: Clinical_trials / Observational_studies Límite: Female / Humans / Male / Middle aged Idioma: En Año: 2015 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Alfa-Fetoproteínas / Trasplante de Hígado / Carcinoma Hepatocelular / Hígado / Neoplasias Hepáticas Tipo de estudio: Clinical_trials / Observational_studies Límite: Female / Humans / Male / Middle aged Idioma: En Año: 2015 Tipo del documento: Article